NCT00443534已完成不适用
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 123
- 试验地点
- 1
- 主要终点
- Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
研究概览
简要总结
This protocol allows subjects who have participated in a previous SU011248 protocol the ability to continue to receive SU011248 after their study has ended.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participation in a previous SU011248 protocol and are judged by the investigator to have the potential to derive clinical benefit by remaining on SU011248 after the prior protocol ends.
排除标准
- •Severe acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study.
研究组 & 干预措施
1
Experimental
干预措施: SU011248 (Drug)
结局指标
主要结局
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
时间窗: Baseline up to Day 28 after last dose of study treatment
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Rollover Protocol for Prior SU011248 ProtocolsSolid TumorsNCT00798889Pfizer314
终止
1 期
A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511Gliomas, MalignantGlioblastoma MultiformeAstrocytomaNCT04327011Tocagen Inc.65
已完成
1 期
An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) ProtocolsAdvanced Solid TumorsNCT01178411ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)60
Available
不适用
Master Rollover Protocol for Continued Safety Assessment of Study DrugCancerNCT02632994Eli Lilly and Company
进行中（未招募）
1 期
A Rollover Study of CC-122Non-Hodgkin LymphomaNCT05688475Bristol-Myers Squibb12